Device Trial Radar · NCT05858801
First Evaluation of a Craniofacial Nerve Stimulation System in Chronic Migraine
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
7
Actual
Start
May 9, 2023
Primary completion
Dec 9, 2023
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Salvia BioElectronicsNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 15, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the safe use of the PRIMUS system in subjects with chronic migraine. This is a single-center, open label, prospective, early feasibility study to collect initial clinical data on the PRIMUS system for the treatment of chronic migraine.
Conditions
- Chronic Migraine
Interventions
PRIMUSDevice
PRIMUS system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationTime frame: 30 days
- Safety EvaluationTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AZ Delta
Roeselare, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.